ASA Bans Voy Ads Over Low Testosterone Claims

“People should be able to trust the health claims they see in ads,” said Catherine Drewett, investigations manager at the Advertising Standards Authority, as the regulator banned five Voy adverts on Wednesday.

The UK’s advertising watchdog banned five Voy adverts for misleading the public about low testosterone.

The adverts promoted Voy’s at-home testosterone blood tests across three posters and two paid-for Facebook ads. They linked common symptoms such as fatigue, irritability, low energy and low sex drive to low testosterone. The ASA found the campaigns exaggerated the connection between symptoms that can have many possible causes and the condition itself.

Voy, an online health platform that also sells testosterone, menopause and weight-loss treatments including Mounjaro and Wegovy, withdrew the adverts while the investigation was under way and said it would not run them again.

The regulator accepted that some symptoms may be more closely tied to low testosterone than others, but said vague indicators should not stand alone as warning signs.

“While some symptoms may be more closely associated with the condition, others were much less specific and shouldn’t have been presented as strong indicators of low testosterone in isolation,” the ASA said in its ruling, published Wednesday.

ASA Bans Voy Ads Over Low Testosterone Claims
Photo: newsfix.co.uk

One Facebook advert went further, claiming that “low testosterone sneaks up on 1 in 4 men over 30”. The ASA called that statistic misleading and not supported by the evidence Voy provided — a finding Voy disputed. The watchdog has also told the company to ensure future adverts do not mislead people about the symptoms or prevalence of low testosterone.

Voy pushed back. “Deliberately conditional” is how the company described its own language, arguing the adverts “did not state or imply that the advertised symptoms were definitively caused by low testosterone”.

Dr Earim Chaudry, chief medical officer for Voy, defended the campaigns.

“Every patient decision at Voy is clinician-led and these campaigns were developed to align with UK advertising standards. We keep all our advertising under continual review to ensure it meets any updated guidance,” he said.

The Tube posters that sparked a backlash

Some of the adverts had already drawn criticism earlier this year when they appeared on the London Underground. Readers called them “ragebait” for lines such as “It’s not him, it’s his hormones” and “Men get hormonal too”. At the time, Voy said it was trying to destigmatise conversations about men’s health.

Wednesday’s ruling also follows a Telegraph exposé earlier this year in which experts warned the claims were exaggerated, unethical and dangerous. In January, Ashley Grossman, professor of endocrinology at the University of Oxford, told The Telegraph he was shocked by the messaging on Voy posters across the underground.

“No NHS body and no pharmaceutical company would dream of advertising testosterone replacement willy-nilly the way these companies do,” Grossman said.

Dr Richard Quinton, an expert in testosterone deficiency, pointed out how easily a misleading result can arise.

“It’s very easy to get a low testosterone level in any healthy man, simply by doing a blood test in the afternoon, after a meal, when unwell from any cause, or after an all-night sit up,” Quinton said.

The NHS position is more measured: testosterone levels in men do fall with age, but this is “unlikely” to cause problems in itself, and while a deficiency in later life can sometimes explain symptoms such as depression, loss of sex drive or erectile dysfunction, they are often not linked, according to the guidance cited in the ruling coverage. True hypogonadism is extremely rare in otherwise healthy men.

The Voy ban is the third strike in the ASA’s investigation into adverts aimed at men worried about their health. In August, the watchdog found misleading claims in adverts for testosterone testing services from two other online providers, BioID Health and Numan Digital Healthcare. Numan’s banned advert falsely claimed that “40 per cent of men with obesity have low testosterone”.

Across more than 1,900 adverts relating to men’s hormonal health and performance, the regulator found a recurring theme of advertisers “playing on insecurities surrounding libido, erectile problems, testosterone and ageing” — some suggesting concerns about masculinity, confidence and relationships, then selling supplements, devices and tests as the fix.

Advertising for low-testosterone tests and services remains permitted. But the ASA said businesses must not “exploit health concerns or play on insecurities to sell products and services”, and that claims must be backed by strong evidence.

“We’ll continue to keep a close eye on advertising in this sector, responding to concerns raised by the public, as well as taking proactive action against ads that break the rules,” the ASA said.

Photo of author

Newsroom

Newsroom at Archyde.

Xi Warns Japan’s Takaichi Is Militarist Threatening Asia

Samsung Galaxy M47 5G Rated for Outdoor Use by Pontianak Post